• My Account
  • Log In
  • Compare Products
Basket
Toggle Nav
Advanced Search
Menu
Account

Rheumocam Oral Suspension Dog 42ml

SKU
1003190
Loading...

Rheumocam 1.5mg/ml Oral Suspension, for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

Rheumocam; INN-Meloxicam (europa.eu)

View more
In stock

Rheumocam 1.5mg/ml Oral Suspension for Dogs containing Meloxicam 1.5mg/ml and Sodium Benzoate 1.5mg is for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.

Shelf-life after first opening the container - 6 months

Do not use after the expiry date stated on the carton and the bottle.

This veterinary medicinal product does not require any special storage conditions

Initial treatment is a single dose of 0.2mg meloxicam/kg bodyweight (i.e 1.33ml/10kg bodyweight)on the first day. Treatment is to be continued once daily by oral administration (at 24 hour interval) at maintenance dose of 0.1mg meloxicam/kg bodyweight (i.e 0.667ml/10kg bodyweight).

For longer term treatment, once clinical response has been observed (after 4 days), the dose can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time.

Particular care should be taken with regard to the accuracy of dosing. Please carefully follow the instructions of the veterinarian.

For oral use. To be administered with food or directly into the mouth. Shake well before use.

The suspension can be given using either of the two measuring syringes provided in the package. The syringes fit onto the bottle and have a kg-bodyweight scale which corresponds to the maintenance dose (i.e. 0.1mg meloxicam/kg bodyweight). Thus for initiation of the therapy on the first day, twice the maintenance volume will be required.

Alternatively therapy may be initiated with Meloxaid 5mg/ml solution for injection.

A clinical response is normally seen within 3-4 days. Treatment should be discontinued after 10 days at the latest, if no clinical improvement is apparent.

Avoid introduction of contamination during use.

People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.

Oral suspension. Each ml contains Meloxicam 1.5 mg and Sodium benzoate 5 mg.

Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in dogs less than 6 weeks of age.
Adverse Reactions
Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood lethargy and renal failure have occasionally been reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
Special Warnings
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Rheumocam must not be administered in conjunction with other NSAIDs or glucocorticosteriods.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the veterinary products used previously.
In the case of overdosage symptomatic treatment should be initiated.
Operator Warnings
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
General precautions
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. For animal treatment only. Keep out of the reach and sight of children.